The participating health insurance companies pursue the goal of concluding discount contracts with all suitable pharmaceutical entrepreneurs in accordance with section 130a paragraph 8 of the German Civil Code V for the active substance adalimumab. The contract is concluded within the framework of the open house biology procedure of health insurance companies:

Individual negotiations on contract content are not conducted, uniform conditions apply. The health insurance companies do not assure individual contracting partners exclusivity. The contract period is a maximum of 18 months starting from 1.8.2021. The contract ends for all participating health insurance companies no later than January 31, 2023, regardless of the date of conclusion of the contract. All further information can be found in the participation and contract documents.

It is possible to join this open house biological process at any time within the contract period.

A contract is concluded with all pharmaceutical companies that meet the requirements of Annex 4 to the contract (self-declaration for approval and for the company) and who confirm this in electronic form in accordance with § 126a BGB.

This announcement does not apply to the award of a public contract within the meaning of the Public Procurement Directive (2014/24 / EC) or the antitrust law. In the interest of the broadest possible information for interested pharmaceutical companies, this announcement is made in the supplement to the Official Journal of the European Union. The procedure designation "Open Procedure" used in the context of this announcement text in accordance with Section IV.1.1) and the specification of the award criteria in accordance with Section II.2.5) are due to the requirements of the notice form and have no further meaning. This, as well as the use of the medium "TED", does not involve any submission to procurement regulations, the validity of which is not mandatory by law or award regulations.